Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.67, $0.17 better than the analyst estimate of $1.50. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.66 billion.

GUIDANCE:

Gilead Sciences sees FY2023 EPS of $6.60-$7.00, versus the consensus of $6.73. Gilead Sciences sees FY2023 revenue of $26-26.5 billion, versus the consensus of $27 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.